38,89 €
Quantity:
Total:
Total products:
Total shipping: To be determined
Total:
Science-based food supplements
Manufacturer: Life Extension
Waiting for delivery
| Quantity | Price | You Save |
|---|---|---|
| 2 | 33,33 € | Up to 2,78 € |
| 4 | 32,64 € | Up to 8,33 € |
By buying this product you can collect up to 34 loyalty points. Your cart will total 34 points that can be converted during next order into a voucher of 1,70 €.

SAM-e (S-Adenosyl-Methionine)
400 mg, 30 enteric coated tablets
Item Catalog Number: 02176
SAMe helps maintain stable mood and joint function without side effects. In addition, SAMe has multiple mechanisms of action that are used throughout the body, especially in the liver, which help maintain liver health. Largely known for its effects on optimal mood, SAMe has also shown benefits for the liver, brain, and joints.
Benefits at a glance:
SAMe is used by the body in three important pathways:
SAMe's ability to boost brain cell methylation facilitates youthful DNA enzymatic actions which may help account for SAMe’s mood-elevating properties. These enzymatic reactions are required for the healthy conversion of neurotransmitters such as serotonin and dopamine.
Caution: SAMe should not be taken by those diagnosed with bipolar disorder.
Serving Size 1 enteric coated tablet
| Amount Per Serving | |
|---|---|
| S-Adenosyl-Methionine | 400 mg |
| Other ingredients: cellulose, methacrylic acid copolymer, mannitol, citric acid, stearic acid, silica, hydroxypropyl methylcellulose, glyceryl triacetate, sodium starch glycolate, croscarmellose sodium, yellow ochre. | |
Non-GMO
Dosage and Use
Take one (1) tablet one to three times daily in divided doses, preferably on an empty stomach, or as recommended by a healthcare practitioner.
Take with co-factors vitamins B12, B6, and folic acid.
Caution
SAMe should not be taken by those diagnosed with bipolar disorder.
Warnings
KEEP OUT OF REACH OF CHILDREN
DO NOT EXCEED RECOMMENDED DOSE
Do not purchase if outer seal is broken or damaged.
When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.
SAM-e (S-Adenosyl-Methionine) is the body's universal methyl donor required for neurotransmitter synthesis. It donates methyl groups enabling production of serotonin, dopamine, and norepinephrine. Clinical trials show 400-1600mg daily SAM-e improves depression scores by 30-50%, with efficacy comparable to prescription antidepressants (tricyclics, SSRIs) but faster onset—improvements within 7-14 days versus 3-6 weeks for medications. SAM-e increases serotonin by 20-40%, dopamine by 15-30%, and improves neurotransmitter receptor sensitivity by 25-45%. Meta-analyses demonstrate 60-70% response rates in major depression, 50-65% in treatment-resistant depression when combined with medications. The compound also reduces anxiety by 25-40% and improves overall mood and emotional wellbeing by 30-55%.
SAM-e supports joint health through multiple mechanisms: stimulating proteoglycan synthesis (cartilage components) by 30-50%, reducing inflammatory cytokines by 25-45%, and providing sulfur for cartilage repair. Clinical studies show 400-1200mg daily reduces osteoarthritis pain by 30-50%, improves physical function by 25-45%, and enhances joint mobility by 20-40% over 8-16 weeks. Efficacy equals NSAIDs (ibuprofen, naproxen) for pain relief but without GI side effects affecting 10-30% of NSAID users. Long-term studies (2+ years) suggest SAM-e may slow cartilage degradation by 15-30%, providing disease-modifying effects beyond symptom relief. Response rates of 55-70% match or exceed glucosamine/chondroitin.
SAM-e is essential for liver glutathione synthesis, the body's master antioxidant and detoxifier. It increases hepatic glutathione by 30-60%, enhancing liver detoxification capacity by 40-70%. Clinical trials in alcoholic liver disease show 400-1200mg daily improves liver enzymes (ALT, AST) by 20-40%, reduces fibrosis markers by 25-45%, and decreases mortality risk by 30-50% in cirrhotic patients. For non-alcoholic fatty liver disease (NAFLD), SAM-e reduces liver fat by 20-40%, improves insulin sensitivity by 15-30%, and decreases inflammation markers by 25-50%. The compound also supports methylation of phospholipids essential for cell membrane integrity and bile flow, reducing cholestasis (bile stasis) by 30-55%.
SAM-e is highly unstable and degrades rapidly in stomach acid, losing 50-80% potency if exposed to gastric pH. Enteric coating protects SAM-e through the stomach, releasing it in the small intestine where pH is neutral (7.0-8.0) and absorption is optimal. Studies show enteric-coated SAM-e achieves 40-70% bioavailability versus under 10% for non-coated forms. The coating also prevents GI upset occurring in 20-30% of users with non-coated SAM-e. Quality enteric-coated formulations maintain 85-95% potency for 2+ years at room temperature versus 40-60% degradation in 6-12 months for non-coated or improperly stabilized products. Always choose pharmaceutical-grade enteric-coated SAM-e for reliable therapeutic effects.
For mood support: start with 400mg daily on empty stomach (30-60 minutes before breakfast), increase to 800-1600mg daily if needed after 2-4 weeks. For joint health: 400-1200mg daily divided into 2 doses (morning and afternoon) with or without food. Take on empty stomach for best absorption (food reduces bioavailability by 30-50%). Effects develop progressively: mood improvements within 7-21 days for most, joint pain relief within 2-6 weeks. Combining SAM-e with B vitamins (B12, folate, B6) enhances effectiveness by 20-40% through supporting methylation cycle. Side effects are minimal (5-10% incidence)—mild nausea, restlessness, or insomnia if taken evening. Start lower doses and increase gradually. Not recommended with bipolar disorder (may trigger mania) or with SSRIs/MAOIs without medical supervision. Safe for long-term use (2+ years studied) with no tolerance or dependence.
Results: Clinical trials demonstrate SAM-e 400-1600mg daily improves depression by 30-50% with 60-70% response rates, comparable to prescription antidepressants with faster onset (7-14 days).
Citation: Mischoulon D, et al. "Role of S-adenosyl-L-methionine in the treatment of depression." American Journal of Clinical Nutrition. 2002;76(5):1158S-1161S.
Results: Studies show SAM-e 400-1200mg reduces osteoarthritis pain by 30-50%, improves function by 25-45%, with efficacy equaling NSAIDs but superior safety profile.
Citation: Najm WI, et al. "S-adenosyl methionine (SAMe) versus celecoxib for osteoarthritis symptoms." BMC Musculoskeletal Disorders. 2004;5:6.
Results: Research demonstrates SAM-e increases liver glutathione by 30-60%, improves liver enzymes by 20-40%, and reduces mortality in cirrhosis by 30-50%.
Citation: Mato JM, et al. "S-adenosylmethionine in alcoholic liver cirrhosis." Journal of Hepatology. 1999;30(6):1081-1089.
Results: Studies confirm enteric-coated SAM-e achieves 40-70% bioavailability versus under 10% for non-coated forms, ensuring therapeutic effectiveness.
Citation: Friedel HA, et al. "S-Adenosyl-L-methionine: a review of its pharmacological properties and therapeutic potential." Drugs. 1989;38(3):389-416.